Safe and efficacy of the use of covered stent for the treatment of iliofemoral disease

Eugenio Stabile, MD, PhD

Professor of Cardiovascular Diseases
Department of Advanced Biomedical Sciences
University “Federico II”, Napoli, Italy
Background

In the treatment of aorto-iliac lesions, Covered stent are preferred when the risk of vessel rupture is high (i.e. calcific, EIA) and when there is a risk for peripheral embolization (i.e. thrombus, friable plaques) through the mesh of conventional the stents.

In the COBEST trial, the use of covered stent was associate to an increased patency rate at follow up.
The Be Graft® Peripheral stent system

This peripheral stent graft system has a cobalt-chrome stent platform is covered with a micro-porous ePTFE membrane.

These features allow to have at the same time a proper radial force, an adequate flexibility and a low profile.
The BeGRAFT -PAD FED II Registry

Aim of this prospective registry was to evaluate safety and efficacy, at one year, of the use of PTFA covered balloon expandable stent the treatment of aortoiliac lesions.

All procedures was performed in AOU Federico II, Naples

From January 2017 to December 2017, 28 patients with symptomatic due Lower Extremity Artery Disease (LEAD) at the aortoiliac locations underwent PTA with implant of a covered stent (Be-Graft, Bentley Innomed GmbH, Germany).
Patients were evaluated up to 12 months with clinical assessment and duplex ultrasound.

1. **Primary endpoint** of the study is primary patency at 12 months, which is defined by the absence hemodynamically significant target lesion stenosis on duplex ultrasound (>50%, Peak systolic velocity ratio ≤ 2.4).

2. **Secondary endpoint** is freedom from target Lesion Revascularization (TLR) at 12 months.
### Baseline characteristic

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>92.8%</td>
</tr>
<tr>
<td>Age</td>
<td>64 ± 0.7</td>
</tr>
<tr>
<td>Diabetes</td>
<td>45.8%</td>
</tr>
<tr>
<td>Hypertension</td>
<td>91.6%</td>
</tr>
<tr>
<td>Hypercholesterolaemia</td>
<td>87.5%</td>
</tr>
<tr>
<td>Smoking history</td>
<td>87.5%</td>
</tr>
</tbody>
</table>

#### CLI (Rutherford Class ≥4)
- **36.4 %**

#### de novo lesions
- **92.8%**

#### Restenosis
- **7.2%**

#### ISRS
- **7.2%**

#### Mean lesion Length (mm)
- **44 ± 32**

#### PACS
- **2,8 ± 0.4**
M.P. 87 y.o: index procedure

LEFT EXTERNAL ILIAC ARTERY ANGIOGRAM

PTA
- BEGRAFT 8 x 37 mm
- BEGRAFT 6 x 38 mm
M.P. 87 y.o: index procedure

FINAL RESULT
Results - In hospital

- Technical success
- MACCE
- MALE
- Clinical success
M.P. 87 y.o: 12-months follow-up
Results - At 12 Months

- Freedom from Restenosis
- MACCE
- MALE
- Freedom from CD-TLR
Conclusion

The results of the Be-Graft PAD FED II Registry suggest that the use of new generation balloon expandable covered stents can be considered a safe and effective therapeutic strategy for the treatment of patients with LEAD at the aortoiliac locations.

These data should be considered hypothesis generators to design large scale registries.
Safe and efficacy of the use of covered stent for the treatment of iliofemoral disease

Eugenio Stabile, MD, PhD

Professor of Cardiovascular Diseases
Department of Advanced Biomedical Sciences
University “Federico II”, Napoli, Italy